Publikationen

Grundlegende Voraussetzung für die flächendeckende Verbesserung der Behandlungskonzepte ist die Publikation der Forschungsergebnisse. iOMEDICO unterstützt die internationalen Richtlinien zu Transparenz und Veröffentlichung von medizinischen Forschungsergebnissen.

Wir präsentieren unsere Daten regelmäßig auf nationalen und internationalen Kongressen. Unsere Publikationen erscheinen in wissenschaftlich renommierten, internationalen Fachzeitschriften. Autoren sind die Studienleiter, Prüfärzte mit besonders hoher Patiententeilnahme und Wissenschaftler von iOMEDICO.

TITEL
STUDIE
JAHR
Final Effectiveness and Safety Results of NABUCCO – Real-World Data from a Non-Interventional, Prospective, Multi-Center Study in 697 Patients with Metastatic Breast Cancer Treated with Nab-Paclitaxel.

Marschner, N., C. Salat, U. Söling, R. Hansen, S. Grebhardt, J. Harde, A. Nusch, and K. Potthoff.

Epub ahead of print: Clinical Breast Cancer 0, no. 0 (15 July 2018). https://doi.org/10.1016/j.clbc.2018.07.010.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Clinical Breast Cancer
NABUCCO
2018
A brief instrument to measure health-related quality of life in patients with bone metastasis: validation of the German version of Bone Metastases Quality-of-Life-10 (BOMET-QoL-10).

Marschner, N., Wilke, J., Reschke, D., Kaiser, F., Schmoor, C., Grugel, R., Boller, E., 2018.

J Med Econ, 21(9), 920–929. doi:10.1080/13696998.2018.1484750

Abstract

Indikation: Other, Sonstige / Veranstaltung: - / Journal: Journal of Medical Economics
ARIE
2018
Effect of hypertension (HTN) on progression-free survival (PFS) in patients (pts) receiving front-line bevacizumab (BEV) for primary advanced ovarian cancer (OC) in the NOGGO single-arm OTILIA study: A post hoc analysis in 808 pts.

Armbrust, R., Wimberger, P., Mustea, A., Oskay-Özcelik, G., Keller, M., Richter, R., Harde, J., Zortel, M., Wegenaer, A., Tome, O., Sehouli, J., North-Eastern German Society of Gynaecological Oncology (NOGGO), 2018.

J Clin Oncol (Meeting Abstracts) 36 (suppl) abstr 5546.

Abstract

Indikation: Other, Ovarialkarzinom, Ovarian Cancer, Sonstige / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
OTILIA
2018
The Prospective Intersectoral National Cohort Study MYRIAM To Study Characteristics, Treatment And Outcome Of Patients With Multiple Myeloma In Germany.

Knauf, W., Engelhardt, M., Losem, C., Lipke, J., Kasper, C., Houet, L., Vannier, C., Jänicke, M., Marschner, N., Dechow, T., Einsele, H., 2018.

HemaSphere 2(S1)(PB2162), 967.

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: EHA / Journal: -
MYRIAM
2018
MANTA – A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer.

Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., Makris, A., Nemsadze, G., Brunt, A.M., Kuemmel, S., Cabrero, I.R., Perelló, A., Kendall, A., Brown, J., Kristeleit, H., Conibear, J., Saura, C., Grenier, J., Máhr, K., Schenker, M., Sohn, J.H., Lee, K.S., Sarker, S.-J., Coetzee, C., Mousa, K., Castan, J.C., 2018.

Cancer Res 78(4 Supplement), GS2-07-GS2-07. doi:10.1158/1538-7445.SABCS17-GS2-07

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: SABCS / Journal: Cancer Research
MANTA
2018
Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.

Knauf, W., Aldaoud, A., Losem, C., Mittermueller, J., Neise, M., Niemeier, B., Harde, J., Trarbach, T., Potthoff, K., 2018.

Leuk. Res. 68, 90–97. doi:10.1016/j.leukres.2018.03.008

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: - / Journal: Leukemia Research
Revlimid-NIS
2018
Prophylaxis of Chemotherapy-induced Neutropenia and Febrile Neutropenia with Lipegfilgrastim in Patients with Non-Hodgkin Lymphoma (NADIR study).

Wolff, T., Schulz, H., Losem, C., Reichert, D., Hurtz, H.-J., Sandner, R., Harde, J., Grebhardt, S., Potthoff, K., Mueller, U., Fietz, T., 2019.

Eur J Hematol. doi:10.1111/ejh.13189

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: - / Journal: European Journal of Hematology
NADIR
2018
Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma – Analyses From the German Clinical RCC-Registry.

Goebell, P.J., Staehler, M., Müller, L., Nusch, A., Scheffler, M., Sauer, A., von Verschuer, U., Tech, S., Kruggel, L., Jänicke, M., Marschner, N., RCC-Registry Group (Tumour Registry of Advanced Renal Cell Carcinoma), 2018.

Clin. Genitourin. Cancer. 16, e1101-e1115.https://doi.org/10.1016/j.clgc.2018.06.006

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: - / Journal: Clinical Genitourinary Cancer
TNK
2018
Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment-Analyses from the German clinical RCC-Registry.

Goebell, P.J., Müller, L., Hübner, A., Harich, H.-D., Boller, E., Koska, M., Jänicke, M., Marschner, N., RCC-Registry Group (Tumour Registry of Advanced Renal Cell Carcinoma), 2018.

Urol. Oncol. 36, 470.e1-470.e9. https://doi.org/10.1016/j.urolonc.2018.07.007

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: - / Journal: Urologic Oncology
TNK
2018
Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).

Wehmeyer, J., Zaiss, M., Losem, C., Schmitz, S., Niemeier, B., Harde, J., Hannig, C.V., Harich, H.-D., Müller, J., Klausmann, M., Tessen, H.W., Potthoff, K., 2018.

Eur J Haematol 101(6), 766–773. doi:10.1111/ejh.13160

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: - / Journal: European Journal of Hematology
PIAZA
2018